Clinical efficacy of caspofungin combined with voriconazole in the treatment of older adult patients with pulmonary fungal infection / 中国基层医药

Objective:To investigate the clinical efficacy of caspofungin combined with voriconazole in the treatment of older adult patients with pulmonary fungal infection and its effects on pulmonary function and inflammatory factors.Methods:A total of 100 patients with pulmonary fungal infection admitted to Hangzhou Ninth People's Hospital from January 2016 to December 2020 were included in this study. They were randomly assigned to undergo treatment with either voriconazole (control group, n = 50) or caspofungin combined with voriconazole (observation group, n = 50) for 14 consecutive days. Clinical efficacy and changes in pulmonary function and inflammatory factors after treatment relative to before treatment were determined in each group. Results:Total response rate in the observation group was significantly higher than that in the control group [90.00% (45/50) vs. 74.00% (37/50), χ2 = 4.33, P < 0.05). After treatment, forced vital capacity, forced expiratory volume in 1 second, and maximum expiratory flow rate in the observation group were (2.31 ± 0.77) L, (79.30 ± 6.72)%, (86.14 ± 7.27)%, respectively, which were significantly higher than (1.78 ± 0.74) L, (73.22 ± 6.56)%, (78.16 ± 7.09)% in the control group ( t = 3.50, 4.57, 5.55, all P < 0.05). Tumor necrosis factor α, interleukin-6, and procalcitonin levels in the observation group were (8.32 ± 1.41) ng/L, (35.19 ± 3.40) μg/L, (1.94 ± 0.78) ng/L, respectively, which were significantly lower than (10.15 ± 1.58) ng/L, (46.09 ± 3.64) μg/L, (2.43 ± 0.84) ng/L in the control group ( t = 6.11, 15.43, 3.02, all P < 0.05). The incidence of adverse reactions in the observation group was 4.0% (2/50), which was significantly lower than 18.0% (9/50) in the control group ( χ2 = 5.00, P < 0.05). Conclusion:Caspofungin combined with voriconazole for the treatment of pulmonary fungal infection in older adult patients can effectively improve pulmonary function, inhibit the inflammatory response, and have no obvious adverse reactions with accurate clinical efficacy.

Clinical effect of Guben-Huoxue decoction on chronic obstructive pulmonary disease / 国际中医中药杂志

Objective@#To explore the clinical effect of Guben-Huoxue decoction on chronic obstructive pulmonary disease (COPD) and its influence on patients'respiratory rehabilitation and quality of life.@*Methods@#A total 108 patients with COPD admitted to our hospital from May 2013 to January 2018 were selected as the research subjects. The patients were divided into control group and observation group by random number table grouping method, 54 in each group. All patients were given basic treatment such as oxygen inhalation, anti-infection, bronchiectasis, and correction of acidosis. The control group was treated with budesonide formoterol powder inhalation, while the observation group was treated with Guben-Huoxue decoction on the basis of the control group. The maximum ventilation volume per minute (MVV), forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), forced expiratory volume in the second (FEV1%) were measured by pulmonary function meter. Adverse reactions were recorded.@*Results@#The difference of FVC, MVV, FEV1%, symptoms, activity ability, disease influence and comprehensive scores in the observation group were significantly greater than those in the control group (t values were 6.480, 13.679, 5.853, 3.743, 5.786, 5.309, 5.058, respectively, all Ps<0.05). The total effective rate (94.4%) in the observation group were significantly higher than those in the control group (79.6%); the total incidence of adverse reactions (9.3%) was significantly lower than that of the control group (25.9%), and the difference was statistically significant (P<0.05).@*Conclusions@#The Guben-Huoxue decoction can improve the clinical symptoms and pulmonary function of COPD patients, promote respiratory rehabilitation and improve the quality of life.

Clinical effect of Guben-Huoxue decoction on chronic obstructive pulmonary disease / 国际中医中药杂志

Objective To explore the clinical effect of Guben-Huoxue decoction on chronic obstructive pulmonary disease (COPD) and its influence on patients'respiratory rehabilitation and quality of life. Methods A total 108 patients with COPD admitted to our hospital from May 2013 to January 2018 were selected as the research subjects. The patients were divided into control group and observation group by random number table grouping method, 54 in each group. All patients were given basic treatment such as oxygen inhalation, anti-infection, bronchiectasis, and correction of acidosis. The control group was treated with budesonide formoterol powder inhalation, while the observation group was treated with Guben-Huoxue decoction on the basis of the control group. The maximum ventilation volume per minute (MVV), forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), forced expiratory volume in the second (FEV1%) were measured by pulmonary function meter. Adverse reactions were recorded. Results The difference of FVC, MVV, FEV1%, symptoms, activity ability, disease influence and comprehensive scores in the observation group were significantly greater than those in the control group (t values were 6.480, 13.679, 5.853, 3.743, 5.786, 5.309, 5.058, respectively, all Ps<0.05). The total effective rate (94.4%) in the observation group were significantly higher than those in the control group (79.6%); the total incidence of adverse reactions (9.3%) was significantly lower than that of the control group (25.9%), and the difference was statistically significant (P<0.05). Conclusions The Guben-Huoxue decoction can improve the clinical symptoms and pulmonary function of COPD patients, promote respiratory rehabilitation and improve the quality of life.

Análise de pico de fluxo de tosse voluntária de pacientes em um hospital de urgências / Analysis of voluntary cough flow peak of patients in an emergency hospital

INTRODUÇÃO: A tosse, voluntária ou reflexa, é um dos principais mecanismos de depuração para proteção das vias aéreas. O pico de fluxo de tosse (PFT) é um método de avaliação específica, mas que vem demonstrando utilidade para avaliar riscos de complicação pulmonares bem como sua gravidade. Variável muito semelhante ao pico de fluxo expiratório cuja principal diferença consiste no fechamento da glote durante a manobra de tosse. Então avaliar a tosse é importante para identificar pacientes com alterações no pico de fluxo de tosse, e consequente risco de complicações pulmonares. OBJETIVO: Analisar o PFT voluntário e parâmetros clínicos e epidemiológicos em uma população internada nas enfermarias de um hospital de urgências. MÉTODOS: Estudo transversal com pacientes internados nas enfermarias de um Hospital Público de Goiânia. Foram coletados dados epidemiológicos e clínicos. O PFT foi mensurado pelo peak flow meter e a avaliação de dor através da Escala de Dor Visual Numérica associada à Escala de Dor de Faces. RESULTADOS: A amostra foi composta em sua maioria por homens 288 (81,36). A média de idade da população estudada foi de 45,91 anos (±20,14). Sessenta e um por cento dos pacientes (219) apresentaram tosse eficaz, e 43 (12,15%) tosse ineficaz, revelou associação com idade, sexo e diagnóstico. CONCLUSÃO: Os pacientes que mais apresentaram alterações na força de tosse foram os idosos, sexo feminino e vítimas acometidas por desordens neurológicas e toracoabdominais. [AU]

INTRODUCTION. Cough, whether voluntary or reflex, is one of the major clearance mechanisms for airway protection. Peak cough flow is a recent and specific evaluation method, but it has been useful for evaluating pulmonary complications as well as their severity. Variable very similar to the peak of expiratory flow whose main difference consists in the closure of the glottis during the maneuver of cough. Therefore, assessing cough is important to identify patients with changes in peak cough flow, and the consequent risk of pulmonary complications. OBJECTIVE: To analyze the peak flow of voluntary cough and its association with clinical and epidemiological parameters in a population hospitalized in the wards of an emergency hospital. METHODS: A cross-sectional study with 354 patients admitted to the wards of a Public Hospital of Goiânia. Epidemiological and clinical data were collected. Optic cough flow was measured by the peak flow meter and the pain assessment using the Numerical Visual Pain Scale associated with the Face Pain Scale. RESULTS: The sample consisted mostly of 288 (81,36) men. The mean age of the study population was 45,91 years (± 20,14). 61, 86% (219) of the patients had effective cough, and 43 (12,15%) had an ineffective cough. CONCLUSION: Patients who presented the greatest changes in coughing strength were the elderly, females and victims of neurological and thoracoabdominal disorders. [AU]

Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis.

BACKGROUND: The Infant Study of Inhaled Saline (ISIS) in CF was the first multicenter clinical trial to utilize infant pulmonary function tests (iPFTs) as an endpoint. METHODS: Secondary analysis of ISIS data was conducted in order to assess feasibility of iPFT measures and their associations with respiratory symptoms. Standard deviations were calculated to aid in power calculations for future clinical trials. RESULTS: Seventy-three participants enrolled, 70 returned for the final visit; 62 (89%) and 45 (64%) had acceptable paired functional residual capacity (FRC) and raised volume measurements, respectively. Mean baseline FEV0.5, FEF75 and FRC z-scores were 0.3 (SD: 1.2), -0.2 (SD: 2.0), and 1.8 (SD: 2.0). CONCLUSIONS: iPFTs are not appropriate primary endpoints for multicenter clinical trials due to challenges of obtaining acceptable data and near-normal average raised volume measurements. Raised volume measures have potential to serve as secondary endpoints in future clinical CF trials.

Estrategias terapéuticas para aumentar la eficacia de la tos en pacientes con enfermedades neuromusculares / Therapeutic strategies to increase the effectiveness of cough

Cough is a natural reflex that protects respiratory airways against infections or mucus retention. Cough maintains an adequate cleaning of the airways and is a mainstay of respiratory therapy. It can be triggered voluntarily by the patient or by a specific cough device. Peak cough flow (PCF) is used to assess the effectiveness of the cough. When this value is below 160 L/min, cough is considered inefficient and becomes a risk factor for respiratory problems. Patients with weak cough, especially those with neuromuscular disease, have in common a low tidal volume and a decreased maximum insufflation capacity. Both factors directly affect the inspiratory phase previous to cough, which is considered vital to obtain the optimum flow for a productive cough. Different therapeutic measures may help to increase cough efficiency among patients with cough weakness. These interventions may be performed using manual techniques or by mechanical devices. The aim of this review is to analyze the different techniques available for cough assistance, set a hierarchy of use and establish a scientific basis for their application in clinical practice.

The effect of vitamin C on bronchoconstriction and respiratory symptoms caused by exercise: a review and statistical analysis.

Physical activity increases oxidative stress and therefore the antioxidant effects of vitamin C administration might become evident in people undertaking vigorous exercise. Vitamin C is involved in the metabolism of histamine, prostaglandins, and cysteinyl leukotrienes, all of which appear to be mediators in the pathogenesis of exercise-induced bronchoconstriction (EIB). Three studies assessing the effect of vitamin C on patients with EIB were subjected to a meta-analysis and revealed that vitamin C reduced postexercise FEV1 decline by 48% (95% CI: 33% to 64%). The correlation between postexercise FEV1 decline and respiratory symptoms associated with exercise is poor, yet symptoms are the most relevant to patients. Five other studies examined subjects who were under short-term, heavy physical stress and revealed that vitamin C reduced the incidence of respiratory symptoms by 52% (95% CI: 36% to 65%). Another trial reported that vitamin C halved the duration of the respiratory symptoms in male adolescent competitive swimmers. Although FEV1 is the standard outcome for assessing EIB, other outcomes may provide additional information. In particular, the mean postexercise decline of FEF50 is twice the decline of FEV1. Schachter and Schlesinger (1982) reported the effect of vitamin C on exercise-induced FEF60 levels in 12 patients suffering from EIB and their data are analyzed in this paper. The postexercise FEF60 decline was greater than 60% for five participants and such a dramatic decline indicates that the absolute postexercise FEF60 level becomes an important outcome in its own right. Vitamin C increased postexercise FEF60 levels by 50% to 150% in those five participants, but had no significant effect in the other seven participants. Thus, future research on the effects of vitamin C on EIB should not be restricted to measuring only FEV1. Vitamin C is inexpensive and safe, and further study on those people who have EIB or respiratory symptoms associated with exercise is warranted.

Aplicação clínica do pico de fluxo da tosse: uma revisão de literatura / Clinical application of peak cough flow: a literature review

Introdução: A tosse é responsável pela manutenção da via aérea livre de secreção e corpos estranhos. O pico de fluxo da tosse (PFT) é o fluxo expirado máximo medido durante uma manobra de tosse por meio de um peak flow meter. A eficácia da tosse depende da magnitude do pico de fluxo. Técnicas de insuflação assistida e de assistência manual à tosse podem aumentar a sua eficácia. Um PFT mínimo de 160 L/minfoi relatado por alguns autores como necessário para manutenção da clearance brônquica e desmame da ventilação mecânica. Objetivo: Realizar uma revisão de literatura sobre a utilização do pico de fluxo da tosse na avaliação da eficácia da tosse em diferentes situações clínicas. Método: Foi utilizado o descritor peak cough flow, durante a pesquisa realizada nas bases de dados Medline, SciELO e LILACS. Resultado:Foi encontrado um total de 36 artigos, sendo 31 selecionados para leitura. Foram selecionados os artigo sem português, espanhol ou inglês. Conclusão: O PFT vem sendo cada vez mais utilizado na avaliação dos doentes neuromusculares e também em outras situações clínicas.

Coughing is responsible for the clearance of secretion and foreign bodies from the respiratory airway. The peak cough flow (PCF) is the maximum expiratory flow measured by a peak flow meter during a coughing maneuver. Coughing effectiveness is dependant on the peak flow's magnitude. Assisted insufflation technique and manually assisted coughing can increase ability to cough. PCF of 160L/min was reported by some authors as the minimum required to clear airway and mechanical ventilation weaning. Objective: The purpose of this review was to research on the use of PCF to evaluate coughing strength in different clinical conditions. Method: The subject headings used was peak cough flow in a search from Medline, SciELO and LILACS databases. Results: It was found a total of 36 papers and 31 bibliographic references in Portuguese, Spanish and English languages were selected. Conclusion: The PCF is more and more measured in neuromuscular disease valuation and in other clinic condition.

Variáveis perioperatórias de função ventilatória e capacidade física em indivíduos submetidos a transplante cardíaco / Perioperative variables of ventilatory function and physical capacity in heart transplant patients

INTRODUÇÃO: O transplante cardíaco é atualmente a única alternativa cirúrgica amplamente aceita para tratar pacientes com insuficiência cardíaca (IC) grave que a terapia medicamentosa otimizada não consiga manter qualidade de vida adequada. OBJETIVO: Descrever e comparar os valores entre pré e pós-operatório, das capacidades física e pulmonar de pacientes que realizaram transplante cardíaco. MÉTODOS: Estudo de coorte retrospectivo composto por indivíduos submetidos ao transplante cardíaco, entre janeiro de 2001 a março de 2005, no IC-FUC/RS. RESULTADOS: Foram incluídos na análise 21 indivíduos. Observou-se redução dos valores de volumes e capacidades pulmonares (VEF1 e CVF) no 1º dia de pós-operatório em relação ao pré-operatório (P<0,001) e recuperação destes valores no 14º dia de pós-operatório (P<0,001). Os valores de força muscular inspiratória demonstraram tendências semelhantes, reduzindo no 1º dia de pós-operatório em relação ao pré-operatório (P< 0,001) e recuperando no 14º pós-operatório (P< 0,001). A capacidade funcional útil, mensurada por meio do teste de caminhada de 6 minutos (T6') mostrou melhora no 14º pós-operatório em relação ao pré-operatório (P< 0,001). CONCLUSÃO: Alterações na função ventilatória de indivíduos submetidos a transplante cardíaco são previsíveis, porém estes recuperam a força de músculos ventilatórios e capacidades pulmonares dentro de duas semanas, além de melhorar a capacidade funcional útil em relação ao préoperatório, sendo o transplante, quando indicado, associado à reabilitação funcional boa estratégia terapêutica.

INTRODUCTION: Heart transplantation is currently the only widely accepted surgical alternative to treat patients with severe heart failure (HF) drug therapy cannot maintain optimal quality of life appropriate. OBJECTIVE: To describe and to compare the values between pre-and postoperative physical capacity and pulmonary patients who underwent heart transplantation. METHODS: A retrospective cohort composed of patients undergoing heart transplantation between January 2001 to March 2005 in IC-FUC/RS. RESULTS: Were included in the 21 individuals. We observed decreased levels of volume and lung capacity (FEV1 and FVC) in the first days after surgery compared to preoperatively (P <0.001) and recovery of these values in the 14th postoperative day (P <0.001). The values of muscle strength showed similar trends in reducing post-operative period compared to preoperative (P <0.001) and recovered on the 14th postoperative day (P <0.001). A useful functional capacity, measured by testing 6-minute walk test (T6') showed improvement in the 14th postoperative day in relation to pre-operatively (P <0.001). CONCLUSION: Changes in ventilatory function of subjects undergoing cardiac transplantation are predictable, but these recover respiratory muscle strength and lung capacity within two weeks, and improve functional capacity useful in relation to pre-operative, the transplantation, when indicated, associated with good functional rehabilitation is very god treatment strategy.

Personal and ambient air pollution exposures and lung function decrements in children with asthma.

BACKGROUND: Epidemiologic studies have shown associations between asthma outcomes and outdoor air pollutants such as nitrogen dioxide and particulate matter mass < 2.5 microm in diameter (PM(2.5)). Independent effects of specific pollutants have been difficult to detect because most studies have relied on highly correlated central-site measurements. OBJECTIVES: This study was designed to evaluate the relationship of daily changes in percent-predicted forced expiratory volume in 1 sec (FEV(1)) with personal and ambient air pollutant exposures. METHODS: For 10 days each, we followed 53 subjects with asthma who were 9-18 years of age and living in the Los Angeles, California, air basin. Subjects self-administered home spirometry in themorning, afternoon, and evening. We measured personal hourly PM(2.5) mass, 24-hr PM(2.5) elemental and organic carbon (EC-OC), and 24-hr NO(2), and the same 24-hr average outdoor central-site(ambient) exposures. We analyzed data with transitional mixed models controlling for personal temperature and humidity, and as-needed beta(2)-agonist inhaler use. RESULTS: FEV(1) decrements were significantly associated with increasing hourly peak and daily average personal PM(2.5), but not ambient PM(2.5). Personal NO(2) was also inversely associated with FEV(1). Ambient NO(2) was more weakly associated. We found stronger associations among 37 subjects not taking controller bronchodilators as follows: Personal EC-OC was inversely associated with morning FEV(1); for an interquartile increase of 71 microg/m(3) 1-hr maximum personal PM(2.5), overall percent-predicted FEV(1) decreased by 1.32% [95% confidence interval (CI), -2.00 to -0.65%]; and for an interquartile increase of 16.8 ppb 2-day average personal NO(2), overall percent-predicted FEV(1) decreased by 2.45% (95% CI, -3.57 to -1.33%). Associations of both personal PM(2.5) and NO(2) with FEV(1) remained when co-regressed, and both confounded ambient NO(2). CONCLUSIONS: Independent pollutant associations with lung function might be missed using ambient data alone. Different sets of causal components are suggested by independence of FEV(1) associations with personal PM(2.5) mass from associations with personal NO(2).

Spirometric changes following the use of pesticides

We compared the respiratory function of 19 pesticide factory workers and a control group of 43 other factory workers in Lebanon. The groups had no difference in smoking status. Baseline measurements of respiratory function showed significantly lower forced expiratory volume and flow rates [FEV1, FEF[25-75%], and FEV1/FVC ratio] among subjects working with pesticides, i.e. obstruction may be linked to chronic exposure to pesticides. After 4 hours of work, all respiratory variables were still significantly lower in pesticide-exposed subjects, but no acute changes in respiratory function were seen. Pesticide-exposed workers had 5.6 times higher risk of abnormal FEV1/FVC ratio and 16.5 higher risk for abnormal FEF[25-75%]. Duration of occupation in the pesticide factory was significantly correlated with abnormal respiratory measures